Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Minimal residual disease in cerebrospinal fluid at diagnosis: a more intensive treatment protocol was able to eliminate the adverse prognosis in children with acute lymphoblastic leukemia

Full text
Author(s):
Biojone, Estefania [1] ; Queiroz, Rosane De Paula [1] ; Valera, Elvis Terci [1] ; Odashima, Newton Satoro [2] ; Takayanagui, Osvaldo Massaiti [2] ; Viana, Marcos Borato [3] ; Tone, Luiz Gonzaga [1] ; Scrideli, Carlos Alberto [1]
Total Authors: 8
Affiliation:
[1] Univ Sao Paulo, Dept Pediat, Ribeirao Preto Med Sch, BR-14048900 Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Dept Neurosci & Behav Sci, Ribeirao Preto Med Sch, BR-14048900 Ribeirao Preto, SP - Brazil
[3] Univ Fed Minas Gerais, Dept Pediat, Belo Horizonte, MG - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Leukemia & Lymphoma; v. 53, n. 1, p. 89-U184, JAN 2012.
Web of Science Citations: 11
Abstract

We analyzed cerebrospinal fluid (CSF) samples from 65 consecutive children with acute lymphoblastic leukemia (ALL) treated according to two different treatment protocols (GBTLI-ALL-93 and -99) with no puncture accident for minimal residual disease (MRD) in the central nervous system (CNS). Minimal residual disease was detected by polymerase chain reaction (PCR) with homo/heteroduplex analysis using consensus primers to IgH and TCR genes. MRD in the CSF at diagnosis was detected by PCR in 46.8% of children with no puncture accident or morphological involvement. In patients treated with GBTLI-ALL-93 a significantly lower 5-year event-free survival (EFS) was demonstrated for those with CSF involvement, in univariate (p = 0.01) and multivariate (p = 0.04) analysis. This observation was not true for patients treated with the more intensive protocol GBTLI-ALL-99 (p = 0.81). These findings suggest that MRD detection in the CSF is a common event in children with ALL. Treatment intensification provided by the GBTLI-ALL-99 apparently overcomes the detrimental effect of CNS minimal residual disease at diagnosis. (AU)

FAPESP's process: 05/02279-6 - Minimal residual disease study in acute lymphoblastic leukemia of children and teenager
Grantee:Carlos Alberto Scrideli
Support Opportunities: Regular Research Grants